Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 7,881 matching trials from the live ClinicalTrials.gov search.
Conditions
Hematological Malignancies
Interventions
omidubicel
Biological
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Maywood, Illinois + 3 more
Conditions
Smoking Cessation, Smoking, Tobacco Cessation
Interventions
NicVAX vaccine, Placebo vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 19 more
Conditions
Recurrent Melanoma
Interventions
radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
39
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Joliet, Illinois + 22 more
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 20 more
Conditions
Non Hodgkin Lymphoma
Interventions
Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
431
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more
Conditions
ALS, ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Davie, Florida • Chicago, Illinois • Boston, Massachusetts + 1 more
Conditions
Primary Biliary Cirrhosis
Interventions
Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
40
States / cities
Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
HU6, Placebo
Drug · Other
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 25 more
Conditions
Lung Cancer
Interventions
placebo, selenium
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
515
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 339 more
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Northridge, California • Riverside, California • Westminster, California + 11 more
Conditions
Critical Limb Ischemia
Interventions
Ixmyelocel-T, Placebo
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
35 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Conditions
Asthma
Interventions
GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg, Placebo MDI, Spiriva Respimat 2.5 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
232
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more
Not listed No phase listed Observational Accepts healthy volunteers

The Circulating Cell-free Genome Atlas Study

NCT02889978
Conditions
Neoplasms, Cancer
Interventions
Not listed
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
20 Years and older
Enrollment
15,254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
139
States / cities
Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 105 more
Active, not recruiting Not applicable Interventional

J-Valve Transfemoral Pivotal Study

NCT06455787
Conditions
Aortic Valve Regurgitation, Aortic Valve Disease Mixed
Interventions
J-Valve Transfemoral (TF) System
Device
Lead sponsor
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
sargramostim
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
87
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
Completed No phase listed Observational Accepts healthy volunteers

Impact of Physical Therapy Intervention on Foot and Ankle Function

NCT04930406
Conditions
Neoplasms, Physical Therapy Modalities, Survivorship
Interventions
Physical therapy
Other
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
7 Years to 30 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Moral Injury Syndrome
Interventions
Building Spiritual Strength, Present Centered Group Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Augusta, Maine + 2 more
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Completed Phase 4 Interventional Results available

Glargine U300 Hospital Trial

NCT03013985
Conditions
Type 2 Diabetes
Interventions
Glargine U300, Glargine U100, Glulisine Insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Predictor of Advanced Subclinical Atherosclerosis

NCT00245284
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
PreMD
Industry
Eligibility
40 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
6
States / cities
Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Conditions
Cardiomyopathy, Coronary Artery Disease, Congestive Heart Failure, Myocardial Infarction
Interventions
Implantable Cardioverter Defibrillator, Optimal Medical Therapy
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
70 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Minneapolis, Minnesota + 2 more
Conditions
Pediatric Growth Hormone Deficiency
Interventions
MOD-4023, Somatropin
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Orange, California • Aurora, Colorado • Centennial, Colorado + 15 more
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more